Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by Stackinstockson Dec 20, 2017 8:33pm

37 Views

Post# 27201003

RE:Bhahaha All-Socks and StackofShyt are Scared Shytless LoL

If you knew you how to read, everything would be in those 3 official documents and it cleearly states Langley is owned by NHS.

Not sure how it is wholly owned when many people on this board have NHS shares sitting in their brokerage account and they are common shares.

Bullboard Posts

StockTalk | Gold Report: A week of mineralized expansion